Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $14MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Dillione Janet | Director | Jan 21 '26 | Sale | $6.88 | 10,000 | $68,800 | 38,473 | Jan 22 09:30 PM |
| Janet Dillione | Director | Jan 21 '26 | Proposed Sale | $6.85 | 10,000 | $68,502 | — | Jan 21 04:42 PM |
| Todisco Joseph | Chief Executive Officer | Jan 16 '26 | Option Exercise | $3.38 | 29,585 | $99,997 | 521,664 | Jan 20 09:28 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.